Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11:35am EDT
Change (% chg)

€0.07 (+0.59%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ABLX.BR


Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)


Beta: 1.60
Market Cap(Mil.): €645.43
Shares Outstanding(Mil.): 54.51
Dividend: --
Yield (%): --


  ABLX.BR Industry Sector
P/E (TTM): -- 63.85 32.90
EPS (TTM): -0.40 -- --
ROI: -20.51 -0.13 14.19
ROE: -41.15 -0.99 15.12
Search Stocks

BRIEF-Ablynx initiates a multinational phase III study with Caplacizumab in patients with acquired TTP

* Initiates a multinational phase III study with Caplacizumab in patients with acquired TTP, a rare blood clotting disorder

29 Sep 2015

Ablynx burns more cash in first half of 2015

BRUSSELS, Aug 27 - Belgian biotech firm Ablynx burnt through more cash in the first half of 2015, as it increased spending on research and clinical trials for its experimental drugs.

27 Aug 2015

BRIEF-Ablynx H1 net loss widens to 15.2 million euros

* Reports H1 revenue and grant income up 73 percent to 38.4 million euros ($43.6 million)

27 Aug 2015

BRIEF-Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody

* Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody, partnered with Abbvie Inc

04 Aug 2015

Belgium's Ablynx triples cooperation deal with Merck & Co

BRUSSELS, July 22 - Belgian biotech group Ablynx on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).

22 Jul 2015

BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co

* Significantly expands its immuno-oncology collaboration with Merck & Co Inc

22 Jul 2015

BRIEF-Oppenheimer Funds announce 3.07% shareholding in Ablynx

* Oppenheimer Funds, Inc. (OFI) notified Ablynx that they have exceeded the 3 percent threshold and now hold 1,672,262 Ablynx shares, which represent 3.07 percent of the current 54,407,572 outstanding shares of Ablynx Source text for Eikon: Further company coverage: (Gdynia Newsroom)

14 Jul 2015

BRIEF-Taube Hodson Stonex Partners announce 5.14% stake in Ablynx

* Taube Hodson Stonex Partners LLP announces 5.14 percent shareholding in Ablynx

01 Jul 2015

BRIEF-Ablynx and Taisho sign license deal on anti-TNFa nanobody (Ozoralizumab) in Japan

* Ablynx and Taisho sign exclusive license agreement for the development and commercialisation of anti-TNFa nanobody (Ozoralizumab) in Japan

30 Jun 2015

BRIEF-Ablynx announces presentations on Caplacizumab

* Ablynx announces presentations on its potential treatment for acquired TTP, Caplacizumab, at the 2015 annual meeting of the ISTH

17 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
Provider : Wright Reports
Provider : GlobalData
Provider : Sadif Analytics Prime
Provider : Sadif Analytics Prime

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks